Marisa Wexler, MS,  senior science writer—

Efgartigimod is entering a Phase 3 clinical trial after data from a proof-of-concept Phase 2 trial showed it outperformed a placebo at easing symptoms and signs of primary Sjögren’s disease, the treatment’s developer said. Argenx shared the data at the European Congress of Rheumatology (EULAR) 2025, held June…

A study found significant associations between eye surface changes and alterations in immune activity throughout the body in people with primary Sjögren’s disease. “These results provide new insights into the relationship between ocular surface and systemic [whole body] status in patients with [primary Sjögren’s disease],” the researchers wrote. The study,…

Cullinan Therapeutics is planning the launch of a clinical trial in the U.S. to test its treatment candidate CLN-978 in people with Sjögren’s disease. The study will be open to Sjögren’s patients whose disease is active and moderate to severe, and who are positive for anti-SSA/Ro antibodies and/or…

Immunovant is planning to launch a potentially registrational clinical trial this summer to test its treatment candidate IMVT-1402 in people with Sjögren’s disease. The company said that its investigational new drug application — a formal request to the U.S. Food and Drug Administration (FDA) seeking permission to start…

April is Sjögren’s Awareness Month, and a U.S.-based nonprofit is gearing up to help the community spread the word about Sjögren’s disease — and the many ways people impacted by this autoimmune condition can get involved. For this year’s awareness month, the Sjögren’s Foundation is inviting supporters…

A rare condition called cerebral venous thrombosis or CVT, characterized by blood clots forming in veins in the brain, can occur in people with primary Sjögren’s disease, a new study reports. The findings suggest that Sjögren’s patients with co-occurring CVT don’t always show well-known Sjögren’s symptoms, such as dry…

Changes in the metabolic activity of certain immune cells may help to drive the inflammatory attacks that cause Sjögren’s syndrome, a recent study reported. According to its researchers, these findings suggest that targeting a specific metabolic pathway in immune cells, called aerobic glycolysis, may help to reduce disease activity…

Injecting the salivary glands with stem cells derived from fatty tissue was shown to ease the symptoms of Sjögren’s syndrome in a small clinical trial. “[Stem cell] therapy can provide relief of oral and eye’s dryness in our trial in a short time and has potential improvement of subjective…

Telitacicept, RemeGen’s experimental under-the-skin injection therapy, significantly reduced disease severity in adults with primary Sjögren’s syndrome (pSS), according to final data from a Phase 2 clinical trial. Results were detailed in the study “Efficacy and safety of telitacicept in primary Sjögren’s syndrome: a randomized,…

The case of a woman who was diagnosed with Sjögren’s syndrome after experiencing unusual symptoms, including hives and joint pain, was described in a recent report. “Our case highlights that rheumatological diseases do not always present with the typical clinical features and require a more detailed physical examination and…